LumiraDx
LumiraDx Shares to be Delisted From Nasdaq
The decision by Nasdaq follows the sale of essentially all of LumiraDx's assets to Roche.
Roche to Acquire LumiraDx Point-of-Care Testing Tech for up to $350M
Roche expects to integrate the POC clinical chemistry and immunoassay tests into its Diagnostics business when the acquisition closes in mid-2024.
LumiraDx Q2 Revenues Fall 53 Percent on Lower COVID-19 Demand
The firm also shipped more than 1,500 new instruments, mostly to US pharmacies to prepare for the upcoming respiratory season.
Axonlab to Distribute LumiraDx Platform in Switzerland, Germany
Axonlab has the right to promote, market, and sell the LumiraDx platform and tests to hospitals, doctors, clinics, private laboratories, and research institutions.
LumiraDx Q1 Revenues Fall 82 Percent but Beat Wall Street Estimate
The company's SARS-CoV-2 antigen test strips accounted for $10.6 million of revenues while its Fast Lab Solutions business contributed $4.3 million.
Mar 21, 2023
LumiraDx Q4 Revenues Fall 65 Percent
Jul 19, 2022
LumiraDx to Publicly Offer 40M Shares
May 12, 2022
LumiraDx Q1 Revenues up 18 Percent
Apr 6, 2022
Oct 27, 2021